Rethinking events in the haemostatic process: role of factor V and TFPI

Haemophilia

Volumn 22, Issue , 2016, Pages 3-8

  Camire, R M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bleeding disorders; coagulation; factor V; factor Va; haemophilia; TFPI

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; PROTEIN TFPIALPHA; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; HEMOSTATIC AGENT; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; THROMBIN; THROMBOPLASTIN;

BLOOD CLOTTING DISORDER; HEMOPHILIA; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; CHEMISTRY; HEMOPHILIA A; METABOLISM; PATHOLOGY;

BLOOD COAGULATION; FACTOR V; HEMOPHILIA A; HEMOSTATICS; HUMANS; LIPOPROTEINS; THROMBIN; THROMBOPLASTIN;

EID: 84978870374     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13004     Document Type: Review

References (61)

1. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1–16.
2. Roberts HR, Ma AD. Overview of inherited hemorrhagic disorders. In: Colman RW, Marder VJ, Clowes AW, Gerorge JN, Goldhaber SZ eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins, 2006: 877–85.
3. Broze GJ Jr. The tissue factor pathway of coagulation: factor VII, tissue factor, and tissue factor pathway inhibitor. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD eds. Haemostasis and Thrombosis. New York: Churchill Livingstone, 1994: 349–77.
4. Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol 2016; 36: 9–14.
5. Thalji N, Camire RM. Parahemophilia: new insights into factor v deficiency. Semin Thromb Hemost 2013; 39: 607–12.
6. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost 2009; 35: 407–15.
7. Bach R, Rifkin DB. Expression of tissue factor procoagullant activity: regulation by cystosolic calcium. Proc Natl Acad Sci USA 1990; 87: 6995–9.
8. Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 2007; 98: 530–42.
9. Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci USA 2013; 110: 17838–43.
10. Camire RM, Bos MHA. The molecular basis of factor V and VIII procofactor activation. J Thromb Haemost 2009; 7: 1951–61.
11. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846–50.
12. Esmon CT. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits and reconstitution of biological activity. J Biol Chem 1979; 254: 964–73.
13. Nesheim ME, Mann KG. Thrombin-catalyzed activation of single chain bovine factor V. J Biol Chem 1979; 254: 1326–34.
14. Dahlback B. Human coagulation factor V purification and thrombin-catalyzed activation. J Clin Invest 1980; 66: 583–91.
15. Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem 1981; 256: 1002–7.
16. Suzuki K, Dahlback B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257: 6556–64.
17. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry 1990; 29: 1118–28.
18. Nesheim ME, Foster WB, Hewick R, Mann KG. Characterization of factor V activation intermediates. J Biol Chem 1984; 259: 3187–96.
19. Oates AM, Salem HH. The regulation of human factor V by a neutrophil protease. Blood 1987; 70: 846–51.
20. Bradford HN, Annamalai A, Doshi K, Colman RW. Factor V is activated and cleaved by platelet calpain: comparison with thrombin proteolysis. Blood 1988; 71: 388–94.
21. Lee CD, Mann KG. Activation/Inactivation of human factor V by plasmin. Blood 1989; 73: 185–90.
22. Yukelson LY, Tans G, Thomassen MCLGD, Hemker HC, Rosing J. Procoagulant activities in venoms from central Asian snakes. Toxicon 1991; 29: 491–502.
23. Gerads I, Tans G, Yukelson LY, Zwaal RFA, Rosing J. Activation of bovine factor V by an activator purified from the venom of Naja Naja Oxiana. Toxicon 1992; 30: 1065–79.
24. Bakker HM, Tans G, Thomassen MCLGD, Yukelson LY, Ebberink R, Hemker HC et al. Functional properties of human factor Va lacking the Asp683-Arg709 domain of the heavy chain. J Biol Chem 1994; 269: 20662–7.
25. Tans G, Nicolaes GAF, Christella M, Thomassen LGD, Hemker HC, van Zonneveld AJ et al. Activation of human factor V by meizothrombin. J Biol Chem 1994; 269: 15969–72.
26. Allen DH, Tracy PB. Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface. J Biol Chem 1995; 270: 1408–15.
27. Samis JA, Garrett M, Manuel RP, Nesheim ME, Giles AR. Human neutrophil elastase activates human factor V but inactivates thrombin-activated human factor V. Blood 1997; 90: 1065–74.
28. Camire RM, Kalafatis M, Tracy PB. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg 1545 optimizes cofactor function by facilitating factor Xa binding. Biochemistry 1998; 37: 11896–906.
29. Rosing J, Govers-Riemslag JWP, Yukelson LY, Tans G. Factor V activation and inactivation by venom proteases. Haemostasis 2001; 31: 241–6.
30. Kalafatis M, Beck DO, Mann KG. Structural requirements for expression of factor Va activity. J Biol Chem 2004; 278: 33550–61.
31. Pittman DD, Marquette KA, Kaufman RJ. Role of the B domain for factor VIII and factor V expression and function. Blood 1994; 84: 4214–25.
32. Marquette KA, Pittman DD, Kaufman RJ. The factor V B-domain provides two functions to facilitate thrombin cleavage and release of the light chain. Blood 1995; 86: 3026–34.
33. Keller FG, Ortel TL, Quinn-Allen MA, Kane WH. Thrombin-catalyzed activation of recombinant human factor V. Biochemistry 1995; 34: 4118–24.
34. Thorelli E, Kaufman RJ, Dahlback B. Cleavage requirements for activation of factor V by factor Xa. Eur J Biochem 1997; 247: 12–20.
35. Steen M, Dahlback B. Thrombin-mediated proteolysis of factor V resulting in gradual B-domain release and exposure of the factor Xa-binding site. J Biol Chem 2002; 277: 38424–30.
36. Siigur J, Aaspollu A, Tonismagi K, Trummal K, Samel M, Vija H et al. Proteases from Vipera lebetina venom affecting coagulation and fibrinolysis. Haemostasis 2001; 31: 123–32.
37. Segers K, Rosing J, Nicolaes GA. Structural models of the snake venom factor V activators from Daboia russelli and Daboia lebetina. Proteins 2006; 64: 968–84.
38. Fay PJ. Factor VIII structure and function. Int J Hematol 2006; 83: 103–8.
39. Kane WH, Devore-Carter D, Ortel TL. Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region. Biochemistry 1990; 29: 6762–8.
40. Toso R, Camire RM. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J Biol Chem 2004; 279: 21643–50.
41. Zhu H, Toso R, Camire RM. Inhibitory sequences within the B-domain stabilize circulating factor V in an inactive state. J Biol Chem 2007; 282: 15033–9.
42. Bos MH, Camire RM. A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem 2012; 287: 26342–51.
43. Bunce MW, Bos MH, Krishnaswamy S, Camire RM. Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides. J Biol Chem 2013; 288: 30151–60.
44. Mann KG, Kalafatis M. Factor V: a combination of Dr. Jekyll and Mr. Hyde. Blood 2002; 101: 20–30.
45. Segers O, Castoldi E. Factor V Leiden and activated protein C resistance. Adv Clin Chem 2009; 49: 121–57.
46. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004–8.
47. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7.
48. Jesty J. The inhibition of activated bovine coagulation factors X and VII by antithrombin III. Arch Biochem Biophys 1978; 185: 165–73.
49. Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci 2012; 17: 262–80.
50. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123: 2934–43.
51. Mast AE, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 1996; 87: 1845–50.
52. Mast AE. Alternatively spliced tissue factor pathway inhibitor: functional implications. Front Biosci (Schol Ed) 2011; 3: 1457–62.
53. Duckers C, Simioni P, Spiezia L, Radu C, Dabrilli P, Gavasso S et al. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood 2009; 115: 879–86.
54. Ndonwi M, Girard TJ, Broze GJ Jr. The C-terminus of tissue factor pathway inhibitor alpha is required for its interaction with factors V and Va. J Thromb Haemost 2012; 10: 1944–6.
55. Schuijt TJ, Bakhtiari K, Daffre S, Deponte K, Wielders SJ, Marquart JA et al. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein. Circulation 2013; 128: 254–66.
56. Maroney SA, Mast AE. New insights into the biology of tissue factor pathway inhibitor. J Thromb Haemost 2015; 13(Suppl 1): S200–7.
57. Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlback B. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIalpha. J Clin Invest 2013; 123: 3777–87.
58. Cunha ML, Bakhtiari K, Peter J, Marquart JA, Meijers JC, Middeldorp S. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood 2015; 125: 1822–5.
59. Carr ME, Tortella BJ. Emerging and future therapies for hemophilia. J Blood Med 2015; 6: 245–55.
60. Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21: 492–7.
61. Oldenburg J, Albert T. Novel products for haemostasis - current status. Haemophilia 2014; 20(Suppl 4): 23–8.